Table 4 Non-haematological toxicity (by patients and cycles)

From: A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

 

Grade (% of patients, n =43) a

Grade (% of cycles, n =246) a

 

1

2

3

4

1

2

3

4

Nausea

53.5

20.9

0

0

30.1

6.1

0

0

Vomiting

20.9

16.3

0

0

8.9

3.7

0

0

Stomatitis

16.3

11.6

0

0

6.9

2.4

0

0

Diarrhoea

44.2

0

0

0

13.8

0

0

0

Constipation

48.8

14.0

2.3

0

20.7

3.7

0.4

0

Asthenia

58.1

37.2

4.7

0

72.4

11.8

0.8

0

Alopecia

0

97.7

4.1

82.1

Neuropathy

48.8

41.9

2.3

0

53.7

18.7

1.2

0

Hand–foot syndrome

46.5

16.3

9.3

0

31.7

10.2

2.8

0

Nail toxicity

23.3

11.6

2.3

0

17.1

8.9

0.4

0

Myalgia

48.8

16.3

2.3

0

32.9

7.7

0.4

0

Arthralgia

53.5

23.3

9.3

0

32.5

11.0

1.6

0

Elevated transaminase

14.0

2.3

0

0

4.9

0.8

0

0

Hyperbilirubinaemia

14.0

4.7

0

0

7.3

1.6

0

0

  1. aNCI CTC version 2.0.